News

LA Fitness, one of the fastest growing health club chains in the U.S., announced that it will host “Action for ALS” in support of Augie’s Quest at more than 650 of its clubs on  Saturday, Feb. 27, 2016. Anyone donating at least $20 that day, whether or not a member, can take…

MediciNova Inc. announced it will present data from its ongoing clinical trial evaluating MN-166 (ibudilast) in both early and advanced stage amyotrophic lateral sclerosis (ALS) patients at the 68th Annual Meeting of the American Academy of Neurology (AAN) April 15-21 at the Vancouver Convention Centre in Vancouver, Canada.

The ALS Finding a Cure Foundation and the ALS Association are partnering for the Grand Challenge, an initiative to develop a biomarker to track TDP43 aggregation — the primary protein aggregate found in the brain and spinal cord of people with amyotrophic lateral sclerosis (ALS). The winning team,…

The ALS Association has announced its new Translational Research Advancing Therapy for ALS (TREAT ALS) Drug Development Contract grant program, which will fund research for the development of new treatments for amyotrophic lateral sclerosis (ALS). According to a press release, the program will support research from early target identification…

Simplesa, a nutrition company established in 2013 after the amyotrophic lateral sclerosis (ALS) community showed its support for its metabolic supplement called the Deanna Protocol, or DP diet, has expanded the Deanna Protocol Bundle Pack choices for consumers. The Deanna Protocol is an all-natural metabolic program developed by Dr. Vincent Tedone, a…

U.S. veterans who fought in the Persian Gulf War of 1990-91 appear to be at an increased risk for amyotrophic lateral sclerosis (ALS), according to report from the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine. The U.S. Department of Veterans Affairs had requested the review, evaluating and summarizing…

Belgian researchers found the downstream effects of a mutation in the gene C9orf72, identified in 2011 as one of the main genetic factors behind amyotrophic lateral sclerosis (ALS). This specific mutation interferes with nuclear transport of proteins in and out of the cell nucleus and contributes to ALS development. About 10 percent of…

Researchers discovered that a metalloproteinase specialized in the degradation of chondroitin sulfate proteoglycans, called ADAMTS-4, promotes neurodegeneration in a mouse model for human amyotrophic lateral sclerosis (ALS). The study, “ADAMTS-4 promotes neurodegeneration in a mouse model of amyotrophic lateral sclerosis,” was published in the journal Molecular Neurodegeneration. ALS,…

Baylor College of Medicine and the Belgium-based biopharmaceutical company UCB announced that they have entered into a strategic partnership, led by Baylor Professor Huda Zoghbi, to discover new medicines to better treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The research alliance is in keeping UCB’s commitment to accelerating the discovery…

The Target ALS Foundation, a collaborative research consortium, received a $5 million matching-gift donation from Biogen to help establish the foundation’s new Industry Fund for ALS Research, supporting a network of private-public research laboratories working to develop effective treatments and, ideally, a cure for amyotrophic lateral sclerosis (ALS). “Biogen is deeply committed to ALS…